A Prospective Randomized, Multi-center Study to Assess the Safety and Efficacy of Mucosta (Rebamipide), in Combination With Omeprazole as Adjuvant Therapy in Gastric Ulcer Patients (MGES)

NCT01150162 Phase 3 COMPLETED

A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.

Details

Lead sponsor	Otsuka Pakistan Limited
Phase	Phase 3
Status	COMPLETED
Enrolment	129
Start date	2010-10
Completion	2012-08

Conditions

• Gastric Ulcer

Interventions

• Rebamipide and Omeprazole
• Omeprazole

Primary outcomes

• Healing rates for gastric ulcer patients via endoscopic examination — 8 weeks treatment plus 4 weeks follow-up
• Improvement or absence of gastric ulcer associated symptoms — 8 weeks treatment plus 4 weeks follow-up
  Improvement or absence of gastric ulcer associated symptoms, i.e. pain, burning, etc.

Countries

Pakistan